Novo Nordisk A-S

Novo Nordisk’s shares plummeted 3.55% after mixed clinical trial data for its new obesity drug Cagrisema failed to demonstrate a clear advantage over competitor Zepbound.

Novo Nordisk has reclaimed its position as Europe’s most valuable company, driven by strategic advancements, innovative treatments, and a strong financial foundation.